ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.680,40
0,40%
S&P 500
5.319,31
2,30%
Dow Jones
39.446,49
1,76%
Euro vs US Dollar
1,09175
-0,09%
Bitcoin
61.887,57
12,46%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) News

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ARQT
DatumZeitQuelleÜberschriftSymbolFirma
05/08/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
05/08/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
05/08/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
02/08/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
02/08/202422h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
02/08/202422h00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
01/08/202422h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
01/08/202422h00GlobeNewswire Inc.Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024NASDAQ:ARQTArcutis Biotherapeutics Inc
29/07/202413h35GlobeNewswire Inc.Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.NASDAQ:ARQTArcutis Biotherapeutics Inc
29/07/202413h30GlobeNewswire Inc.Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic DermatitisNASDAQ:ARQTArcutis Biotherapeutics Inc
24/07/202422h10Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ARQTArcutis Biotherapeutics Inc
23/07/202414h00GlobeNewswire Inc.Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and OverNASDAQ:ARQTArcutis Biotherapeutics Inc
22/07/202414h00GlobeNewswire Inc.Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOLNASDAQ:ARQTArcutis Biotherapeutics Inc
09/07/202422h53GlobeNewswire Inc.FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of AgeNASDAQ:ARQTArcutis Biotherapeutics Inc
09/07/202414h00GlobeNewswire Inc.Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic DermatitisNASDAQ:ARQTArcutis Biotherapeutics Inc
03/07/202422h00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
18/06/202422h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
18/06/202422h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
18/06/202422h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
18/06/202422h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
10/06/202420h30GlobeNewswire Inc.Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
06/06/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
05/06/202422h00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
05/06/202414h00GlobeNewswire Inc.Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
04/06/202420h03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/06/202414h00GlobeNewswire Inc.Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
30/05/202401h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
28/05/202421h54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
28/05/202413h00PR Newswire (Canada)Arcutis Canada annonce l'acceptation aux fins d'examen par Santé Canada de la présentation de la crème de roflumilast à 0,15 % pour le traitement de la dermatite atopique chez les adultes et les enfants âgés de 6 ans et plusNASDAQ:ARQTArcutis Biotherapeutics Inc
20/05/202423h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ARQT

Kürzlich von Ihnen besucht

TG
NOV
Novo Nordisk
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
DBK
Deutsche Bank
NASDAQ
NVDA
NVIDIA
NASDAQ
TSLA
Tesla
USOTC
BASFY
BASF (QX)
TG
ALV
Allianz
USOTC
BNPQY
BNP Paribas (QX)
DBI
SDXP
SDAX
COIN
SOLUSD
Solana
NASDAQ
GOOGL
Alphabet
CCOM
SILVER
SILVER
TG
D7G
Nel ASA
NYSE
NKE
Nike
TG
RHM
Rheinmetall
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten